Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs iShares 0 3 Month Treasury Bond ETF (SGOV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs iShares 0 3 Month Treasury Bond ETF — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while iShares 0 3 Month Treasury Bond ETF trades at $100.55 (market cap $115.19B). The key difference: iShares 0 3 Month Treasury Bond ETF is far larger — about 118.4× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and iShares 0 3 Month Treasury Bond ETF is more actively traded (18,240,700 versus 4,325,710). Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and iShares 0 3 Month Treasury Bond ETF for 51 Days on average.
| MRVI | SGOV | |
|---|---|---|
Market Cap | $972.90M | $115.19B |
Volume | 4,325,710 | 18,240,700 |
Sector | Health | Fixed Income |
52-Week High | $9.00 | $100.72 |
52-Week Low | $2.83 | $100.28 |
Typical Hold Time | 0 Days | 51 Days |
Enterprise Value | $1.08B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
SGOV, the iShares 0-3 Month Treasury Bond ETF, trades at $100.52 with no price change. The technical outlook is bearish, driven by moving averages, while oscillators are neutral. Recent corporate actions include scheduled dividend payments through late 2026. Market sentiment is influenced by a significant bond selloff and rising Treasury yields, with institutional activity showing a reduction in holdings by Envestnet Asset Management.
The outlook for SGOV is cautious amid a challenging bond market environment. Investment opportunities lie in its short-duration Treasury exposure during rate volatility, but risks include prolonged high interest rates and inflation pressures. Investors should weigh the ETF's stability against macroeconomic headwinds impacting fixed income.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About iShares 0 3 Month Treasury Bond ETF
SGOV provides exposure to ultra-short-term U.S. Treasury bills with maturities of three months or less. It functions as a high-liquidity cash alternative, seeking to provide current income while maintaining a stable net asset value and minimal interest rate risk.
Read more on SGOV →
